In fact, the BCR/ABL1 tyrosine kinase inhibitor (TKI) imatinib is effective in most patients with newly diagnosed Ph+ ALL, and sometimes even in patients with chemotherapy-resistant or relapsed Ph+ ALL, especially when applied in combination with conventional chemotherapy [7-13]. This evidence concerns the gene BCR and acute lymphoblastic leukemia.